XML 68 R56.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Schedule of Segment Revenue, Loss and Significant Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Collaboration revenue $ 76,320     $ 30,017     $ 126,354 $ 48,167
General and administrative 10,209     10,562     34,948 32,195
Total operating expenses 41,616     52,774     145,359 153,446
Net income (loss) from operations 34,704     (22,757)     (19,005) (105,279)
Interest income 2,924     5,324     10,991 14,531
Non-cash interest expense (22,515)     (15,413)     (60,182) (32,683)
Other (expense) income, net 0     (5)     5,433 (7)
Total other expense, net (19,591)     (10,094)     (43,758) (18,159)
Income (loss) before income taxes 15,113     (32,851)     (62,763) (123,438)
Provision for income taxes 0     0     (83) (9)
Segment net income (loss) 15,113 $ (38,630) $ (39,329) (32,851) $ (46,660) $ (43,936) (62,846) (123,447)
Reportable Segment                
Segment Reporting Information [Line Items]                
Collaboration revenue 76,320     30,017     126,354 48,167
Research and development 31,407     42,212     110,411 121,251
General and administrative 10,209     10,562     34,948 32,195
Total operating expenses 41,616     52,774     145,359 153,446
Net income (loss) from operations 34,704     (22,757)     (19,005) (105,279)
Interest income 2,924     5,324     10,991 14,531
Non-cash interest expense (22,515)     (15,413)     (60,182) (32,683)
Other (expense) income, net 0     (5)     5,433 (7)
Total other expense, net (19,591)     (10,094)     (43,758) (18,159)
Income (loss) before income taxes 15,113     (32,851)     (62,763) (123,438)
Provision for income taxes 0     0     (83) (9)
Segment net income (loss) 15,113     (32,851)     (62,846) (123,447)
Reportable Segment | External                
Segment Reporting Information [Line Items]                
Research and development 18,620     30,051     71,385 86,455
General and administrative 2,247     2,529     10,223 6,980
Reportable Segment | Rosnilimab                
Segment Reporting Information [Line Items]                
Research and development 7,070     14,188     37,709 37,161
Reportable Segment | ANB033                
Segment Reporting Information [Line Items]                
Research and development 7,519     1,631     15,248 7,276
Reportable Segment | ANB101                
Segment Reporting Information [Line Items]                
Research and development 1,784     687     5,305 1,631
Reportable Segment | ANB032                
Segment Reporting Information [Line Items]                
Research and development (362)     7,239     3,282 20,381
Reportable Segment | Imsidolimab                
Segment Reporting Information [Line Items]                
Research and development (1,204)     2,389     (2,360) 8,752
Reportable Segment | Preclinical and other unallocated costs                
Segment Reporting Information [Line Items]                
Research and development 3,813     3,917     12,201 11,254
Reportable Segment | Internal                
Segment Reporting Information [Line Items]                
Research and development 12,787     12,161     39,026 34,796
General and administrative $ 7,962     $ 8,033     $ 24,725 $ 25,215